GlassScriptPhysician profile
Marisa Anne Gardner
NPI 1477882587
$1,857.26
in general payments reported to CMS, 2019-2025
13 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $104 · 2021: $180 · 2022: $357 · 2023: $379 · 2024: $333 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $606.11 | 2022-2025 | |
| Neurelis, INC. | $364.99 | 2022-2025 | Valtoco |
| Greenwich Biosciences, INC. | $334.61 | 2019-2021 | |
| Zogenix INC. | $113.39 | 2020-2021 | |
| Ucb, INC. | $94.62 | 2023-2025 | Fintepla, Briviact |
| Sk Life Science, INC. | $89.42 | 2024-2025 | |
| Immedica Pharma US, INC. | $66.98 | 2023-2024 | |
| Mallinckrodt Enterprises LLC | $51.85 | 2019 | |
| Sumitomo Pharma America, INC. | $38.54 | 2023 | Aptiom |
| Acadia Pharmaceuticals INC | $27.72 | 2024 | Daybue |
| Aquestive Therapeutics, INC. | $26.94 | 2025 | |
| Biogen, INC. | $26.64 | 2022 | |
| Biomarin Pharmaceutical INC. | $15.45 | 2023 | Brineura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marisa Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.